



Lack of the major multifunctional catalase KatA in *P.aeruginosa* accelerates evolution of antibiotic resistance in ciprofloxacin-treated biofilms

Ahmed, Marwa N; Porse, Andreas; Abdelsamad, Ahmed; Sommer, Morten Otto Alexander; Høiby, Niels; Ciofu, Oana

Published in:
Antimicrobial Agents and Chemotherapy

Link to article, DOI:
[10.1128/AAC.00766-19](https://doi.org/10.1128/AAC.00766-19)

Publication date:
2019

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Ahmed, M. N., Porse, A., Abdelsamad, A., Sommer, M. O. A., Høiby, N., & Ciofu, O. (2019). Lack of the major multifunctional catalase KatA in *P.aeruginosa* accelerates evolution of antibiotic resistance in ciprofloxacin-treated biofilms. *Antimicrobial Agents and Chemotherapy*, 63(10), Article e00766-19. <https://doi.org/10.1128/AAC.00766-19>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 Lack of the major multifunctional catalase KatA
2 in *P.aeruginosa* accelerates evolution of
3 antibiotic resistance in ciprofloxacin-treated
4 biofilms

5
6 **Marwa N.Ahmed^{1,2}, Andreas Porse³, Ahmed Abdelsamad^{4,5}, Morten Sommer³, Niels Høiby^{1,6}**
7 **and Oana Ciofu^{1*}**

8 1. Costerton Biofilm Center, Department of Immunology and Microbiology, University of
9 Copenhagen, Copenhagen, Denmark.

10 2. Department of Microbiology, Faculty of Agriculture, Cairo University, Giza, Egypt.

11 3. Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark,
12 Lyngby, Denmark.

13 4. Department of Genetics, Faculty of Agriculture, Cairo University, Giza, Egypt

14 5. Department of Biology, University of Copenhagen, Copenhagen, Denmark

15 6. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark

16 **Key words:** *P. aeruginosa*, biofilm, catalase mutant, oxidative stress, antibiotic resistance

17

Evolution of resistance in *P. aeruginosa* $\Delta katA$ biofilms

Ahmed, M. et al.

18

19 Corresponding author*:

20 Oana Ciofu, MD, PhD, Dr.med.

21 Costerton Biofilm Center.

22 University of Copenhagen.

23 Panum Inst., 24.1

24 Blegdamsvej 3

25 2200 N

26 Copenhagen N

27 Denmark

28 ociofu@sund.ku.dk

29 45 29217367

30

31

32

33

34

35

36 **Abstract**

37 During chronic biofilm infections, *Pseudomonas aeruginosa* are exposed to increased oxidative
38 stress as a result of the inflammatory response. As reactive oxygen species (ROS) are mutagenic,
39 the evolution of resistance to ciprofloxacin (CIP) in biofilms under oxidative stress conditions was
40 investigated. We experimentally evolved six replicate populations of *P. aeruginosa* lacking the
41 major catalase KatA in colony biofilms and stationary-phase cultures for seven passages in the
42 presence of sub-inhibitory levels (0.1 mg/L) of CIP or without CIP (eight replicate lineages for
43 controls) under aerobic conditions.

44 In CIP-evolved biofilms, a larger CIP resistant subpopulation was isolated in $\Delta katA$ compared to
45 WT PAO1 population suggesting oxidative stress as a promoter of antibiotic resistance
46 development.

47 A higher number of mutations identified by population sequencing were observed in evolved $\Delta katA$
48 biofilm populations (CIP and control) compared to WT PAO1 evolved under same conditions.
49 Genes involved in iron assimilation were found to be exclusively mutated in CIP-evolved $\Delta katA$
50 biofilm populations, probably as a defense mechanism against ROS formation resulting from
51 Fenton reactions. Furthermore, a hypermutable lineage due to *mutL* inactivation developed in one
52 CIP-evolved $\Delta katA$ biofilm lineage.

53 In CIP-evolved biofilms of both $\Delta katA$ and WT PAO1, mutations in *nfxB*, the negative regulator of
54 the MexCD-OprJ efflux pump were observed while in CIP-evolved planktonic cultures of both
55 $\Delta katA$ and WT PAO1, mutations in *mexR* and *nalD*, regulators of MexAB-OprM efflux pump, were
56 repeatedly found.

57 In conclusion, these results emphasize the role of oxidative stress as an environmental factor that
58 might increase the development of antibiotic resistance in *in vivo* biofilms.

59 **Introduction**

60 Antibiotic resistance is considered a major threat to modern medicine, challenging the treatment of
61 common bacterial infections. Evolution of antibiotic resistance has primarily been studied in liquid
62 cultures; however, in most natural environments and in some chronic infections bacteria are
63 growing in biofilms.

64 Biofilm-grown *P. aeruginosa* experience heterogeneous physiological and metabolic conditions in a
65 compartmentalized environment, which are not encountered in planktonic liquid cultures. These
66 biofilm-specific conditions cause differences in the mutation supply and in the selective pressures
67 acting on biofilm forming cells compared to cells growing in planktonic cultures, which might
68 influence the evolution of antimicrobial resistance.

69 Distinct bacterial subpopulations have been described in biofilms with a metabolically active
70 population at the biofilm surface and a metabolically inactive population in the deeper layers of the
71 biofilm (1). In addition, a steep oxygen gradient, with decreasing levels from the surface to the
72 deeper layers is observed in the colony- biofilm model (2). The described endogenous oxidative
73 stress in biofilms (3,4) is most probably occurring in the superficial layers of the biofilm, where
74 enough oxygen is present and cells are metabolically active. In microaerophilic or anaerobic
75 conditions, as inside microcolonies, *P. aeruginosa* is able to respire on nitrogen oxides in the
76 presence of nitrate and bacterial cells may be exposed to nitrosative stress.

77 Among antibiotics that promote the evolution of resistance, fluoroquinolones such as ciprofloxacin
78 (CIP) are of particular concern because they directly interfere with DNA replication by binding
79 gyrases and topoisomerase IV and hence may encourage replication errors that are the major source
80 of mutations. Gyrases bound with fluoroquinolones molecules result in cross-linked protein-DNA
81 complexes containing broken DNA that induces an SOS response which can contribute through

82 activation of error-prone DNA polymerases to elevated mutation rates(5). In addition, CIP treatment
83 causes increased intracellular reactive oxygen species (ROS) levels in planktonic cultures (6,7). In
84 biofilms, antibiotic-induced ROS production have been described during treatment with quinolones
85 in *P. aeruginosa* (8) and *Proteus mirabilis* (9) and for aminoglycosides in *Burkholderia cepacia*
86 complex (10).

87 It is widely accepted that patients with cystic fibrosis (CF) and chronic *P. aeruginosa* lung infection
88 are exposed to increased oxidative stress mainly driven by chronic inflammation with
89 polymorphonuclear leukocytes, as a source of ROS and a CF-related deficit in the anti-oxidants,
90 such as glutathione, which further increases the inflammatory response, as we have previously
91 shown in animal models (11). Thus, the *P. aeruginosa* biofilms in the CF lungs are exposed to an
92 oxidative stress environment and our study aims at reproducing *in vitro* the oxidative stress by
93 investigating the evolution of antibiotic resistance in *P. aeruginosa* lacking the major catalase
94 KatA, an important anti-oxidant defence system.

95 Given that ROS can damage DNA, membranes, lipids and proteins, *P. aeruginosa* possess different
96 antioxidant defenses to survive during aerobic growth and under antibiotic attack, one of them
97 being the *katA*- encoded major catalase. *P. aeruginosa* has three differentially evolved catalase
98 genes, *katA*, *katB*, and *katE* (*katC*). KatA is the major, constitutively expressed catalase, which is
99 highly produced in all phases of growth but increased upon the stationary growth phase (12). KatA
100 is important for the resistance of *P. aeruginosa* growing in planktonic and biofilm states when
101 exposed to H₂O₂ at high concentrations(12). KatB is induced in both planktonic and biofilm cells in
102 response to H₂O₂ exposure, but plays a relatively small role in biofilm resistance (12,13).

103 It has been suggested that the bactericidal effect of beta-lactams, fluoroquinolones and
104 aminoglycosides have a ROS-dependent component (14), although the significance of this has been

105 challenged (15,16)(17). Biofilms formed by mutants lacking anti-oxidants systems, such as
106 catalases (*katA* for *P. aeruginosa* and *kat B* for *B. cepacia*) showed increased sensitivity to
107 antibiotics (8,10) and this is regarded as solid indication for a contribution of ROS to the
108 bactericidal effect of antibiotics.

109 In addition, It has been shown in biofilms that anti-oxidant systems, such as catalases and
110 superoxide dismutases, are up regulated by the activation of the stringent response (18,19). This
111 suggests that inhibiting oxidative stress is an important strategy used by biofilm forming bacteria to
112 increase antibiotic tolerance. Moreover, the analysis of gene expression of *P. aeruginosa* biofilms
113 revealed that antioxidant enzymes including *katA* are downregulated during the biofilm growth in
114 comparison to planktonic culture (2).

115 It has been shown that KatA catalase, besides its role in protection against ROS-dependent
116 mutagenesis, it also plays a critical role in nitric oxide buffering produced under anaerobic
117 respiration in the presence of nitrate (20). Recently, two different promoters of *katA* have been
118 identified in *P. aeruginosa*, one coping with ROS produced under aerobic respiration and the other
119 with reactive nitrogen species (RNS) produced under anaerobic respiration (21).

120 As the antibiotic-tolerant biofilm-grown *P. aeruginosa* are using both aerobic and microaerophilic
121 respiration, the hypothesized production of mutagenic ROS and RNS in the different biofilm layers
122 might lead to increased mutagenesis and faster development of antibiotic resistance in a Δ *katA*
123 mutant.

124 To investigate the role of KatA in biofilm mutagenesis and development of resistance to antibiotics,
125 we experimentally evolved a catalase mutant (*katA*) of *P. aeruginosa* (22) in colony-biofilm in
126 aerobic and anaerobic conditions in the presence and absence of sub-inhibitory concentrations of

127 CIP. In addition, evolution in the presence and absence of antibiotic was conducted in stationary-
128 phase aerobic planktonic cultures

129 In the present study, we show that the CIP resistant population was larger in $\Delta katA$ than in WT
130 PAO1 aerobic biofilms. Population sequence showed higher number of mutations in $\Delta katA$
131 populations compared to WT PAO1 suggesting that lack of catalase Kat A might promote
132 development of antibiotic resistance in *P. aeruginosa* aerobic biofilms. However, CIP-resistant
133 mutants occurred also during anaerobic evolution of WT PAO1 biofilms suggesting that
134 development of resistance to CIP can occur even in the absence of oxygen. In addition, we show
135 that similarly to an experimental evolution study of wild-type *P. aeruginosa* PAO1(23), a larger
136 CIP resistant population developed in $\Delta katA$ biofilm compared to planktonic cultures confirming
137 the biofilm mode of growth as a promoter of low-level resistance development.

138 **Materials and methods**

139 **Bacterial strains, media and antibiotics**

140 *P. aeruginosa* $\Delta katA$ strain (22) (planktonic MIC ciprofloxacin=0.094 mg/L) was used to test the
141 development of antibiotic resistance during experimental evolution in the colony-biofilm model
142 (24,23) and in planktonic batch cultures. Both biofilms and planktonic cultures were grown in Luria
143 Bertani (LB) media and exposed to 0.1 mg/L CIP (Ciprofloxacin hydrochloride; Bayer; Germany).
144 The minimal inhibitory concentration for a 48h stationary $\Delta katA$ was 0.2 mg/L and the minimal
145 biofilm inhibitory concentration was 0.5 mg/L. The spontaneous mutation rate to 0.5 mg/L CIP was
146 1×10^{-8} for PAO1 and 1.4×10^{-8} for $\Delta katA$, as measured by fluctuation test.

147 **Experimental evolution of colony-biofilm and planktonic cultures.**

148 The experimental evolution of colony-biofilms and planktonic cultures were conducted as
149 previously described (23). In short, a single colony of *P. aeruginosa* $\Delta katA$ was used to inoculate
150 LB for an overnight culture. Five μ l of the diluted overnight culture containing approximately 10^6
151 cells (OD600 adjusted to 0.05 and diluted 1:10) was spot-inoculated on the top of polycarbonate
152 membrane filters (Whatman[®] Nuclepore Track-Etched Membranes, 25 mm diameter, 0.2 μ m pore
153 size) and incubated at 37⁰C to form 48 h colony-biofilms on LB plates. Membranes bearing 48 h
154 colony-biofilms were transferred to fresh LB plates with either 0.1 mg/L CIP (1/5 minimal biofilm
155 inhibitory concentrations) (CIP) or without CIP for 48h (CTRL) (passage 0 consisted of a 4 days
156 old biofilm; 2 days on LB followed by 2 days on LB with CIP). Every 48h the CIP and CTRL
157 membranes were transferred in 10 ml tubes with saline and biofilms were dispersed by vortex and
158 sonication. After adjusting the OD600 to 0.005 the bacterial suspension of CTRL biofilms was used
159 to start new biofilms on LB plates without antibiotics (CTRL). The bacterial suspensions of CIP
160 biofilms were used to start new biofilms on plates with 0.1 mg/L CIP (CIP).

161 A total of seven exposures (from passage 0 (P0) to passage 6 (P6)) to CIP with 6 independent
162 lineages were performed.

163 Two parallel lineages of WT PAO1 and *P. aeruginosa* $\Delta katA$ were also evolved in anaerobic
164 chamber (Whitley A85 anaerobic workstation) for 7 passages (as described). To allow bacterial
165 growth by denitrification, the LB plates were supplemented with 1mM KNO₃.

166 After each 48h, the CFU counts for each biofilm population were measured and the disrupted
167 biofilm populations were kept in 20 % glycerol at -80⁰C until further analysis.

168 Planktonic experiments were conducted in aerobic conditions with the same experimental design as
169 implemented with biofilm cultures. Briefly, 5 μ l of an overnight culture of single colony of *P.*
170 *aeruginosa* $\Delta katA$ was used to inoculate 10 ml LB media and incubated for 48h with shaking on an

171 orbital shaker (180 rpm) at 37°C. From the 48 h culture two flasks were inoculated: one with 0.1
172 mg/L CIP (CIP) and one in LB (CTRL). From CIP stationary cultures, every 48h new planktonic
173 cultures were established in flasks with CIP (CIP). From CTRL stationary cultures, every 48 h new
174 planktonic cultures were established in flask with LB. This was repeated for 6 passages (P1 to P6).

175 **Population analysis**

176 Bacterial populations (100 μ l of different dilutions) obtained after sonication and vortex of
177 membranes containing colony-biofilms or of planktonic cultures from each passage and treatment
178 group were plated on LB plates to estimate the size of the bacterial population and on LB plates
179 containing 0.5, 1 and 2 mg/L CIP, to estimate the size of the resistant subpopulations (growing on
180 CIP concentrations higher than the MIC of the strain *P. aeruginosa* $\Delta katA$). The size of the
181 resistant population was expressed as % of the total bacterial population and calculated by dividing
182 the CFU/ml on CIP by the CFU/ml on LB and multiplied by 100.

183 Three colonies were selected from the plates with the highest CIP concentrations allowing growth,
184 passed twice in antibiotic free media and the minimum inhibitory concentrations (MIC) of CIP were
185 determined by performing E-test (Biomerieux) according to the manufacturer.

186 **Mutation frequencies and rates determination**

187 The mutation frequencies of the evolved populations after each passage were investigated on LB
188 plates containing rifampicin (300 mg/L), as previously described (25). A population was considered
189 hypermutable when the mutation frequency was 20-fold higher than the mutation frequency of the
190 reference strain PAO1 ($\geq 3 \times 10^{-7}$). The mutation rates were determined by a fluctuation test as
191 previously described (26) and calculations were performed using bz-rates web-tool
192 (<http://www.lcqb.upmc.fr/bzrates>).

193 **Genome sequencing of aerobically evolved bacterial populations**

194 The genome sequence was performed as previously described (23). In short, The CIP evolved
195 populations (after 7 passages in the presence of 0.1 mg/L CIP) from four *P. aeruginosa* $\Delta katA$
196 biofilm lineages and three planktonic lineages were grown on LB plates containing 1 mg/L CIP for
197 48 h to enrich for the resistant subpopulation. The CTRL evolved biofilm and planktonic
198 populations (four lineages/condition) were grown on LB plates. All colonies for each population
199 were collected in 3 ml saline (0.9% NaCl) for genomic DNA extraction using Genra puregene
200 yeast/bacteria DNA purification kit. The DNA was prepared for sequencing using the Illumina
201 TruSeq DNA Nano kit and sequenced on an Illumina MiSeq yielding a coverage of approximately 5
202 million reads per sample. Sequencing reads were mapped to the reference genome of *P. aeruginosa*
203 PAO1 (GenBank accession. NC_002516) and single and multiple nucleotide variants (SNVs and
204 MNVs) were called using CLC genomic workbench (Qiagen). Mutations present in the evolved
205 $\Delta katA$ CTRL populations were filtered out from the genome of the CIP evolved populations
206 (biofilm and planktonic). R (version 3.2.5) was used for further statistical analysis of the mutations
207 detected in each population and all mutations occurring in > 10% of the reads were included in the
208 analysis.

209 The Pseudomonas Genome Database was used for gene function analysis. dN/dS, the ratio of the
210 rate of nonsynonymous substitutions (dN) to the rate of the synonymous substitutions (dS), was
211 calculated as a measure of the selection pressure acting on the protein-coding genome, as previously
212 described, assuming that 25% of all single-nucleotide polymorphisms (SNP) result in synonymous
213 changes (27). dN/dS is expected to be >1 if natural selection promotes changes in protein sequences
214 and <1 if natural selection suppresses changes.

215 Sequencing of *nfxB* was performed on CIP resistant colonies selected from anaerobic experiments,
216 as described previously (28).

217 **Statistical analysis**

218 Graphs and statistical analysis were done using GraphPad Prism 7 software and R (version 3.2.5).
219 We conducted D'Agostino Pearson to check for normal distribution and Student t-test was used for
220 comparisons among populations (comparing CIP populations to CTRL populations and CIP biofilm
221 populations to CIP planktonic populations) and to compare the level of resistance at different
222 exposure time points (passages). The differences were considered significant when the p-value was
223 ≤ 0.05 . Error bars in all graphs represent the standard error of the mean.

224

225 **Results**

226 **Development of a larger CIP resistant subpopulation in aerobically evolved $\Delta katA$ *P.* 227 *aeruginosa* biofilms compared to planktonic cultures**

228 The development of CIP resistant subpopulations during the experimental evolution in the presence
229 or absence of 0.1 mg/L CIP was investigated by plating the evolved biofilm and planktonic $\Delta katA$
230 populations (six and three replicates, respectively), at different passages on LB plates containing
231 0.5, 1 and 2 mg/L CIP.

232 $\Delta katA$ CIP-biofilm evolved populations showed a significantly higher resistant subpopulation in
233 comparison to $\Delta katA$ CIP-planktonically evolved population on 0.5 and 1 mg/L CIP (p=0.002 and
234 0.003 respectively, t-test) (Figure 1A). The dynamics of resistance development during passages
235 showed that in comparison to $\Delta katA$ CIP-planktonic populations, $\Delta katA$ CIP-biofilm populations
236 developed a significantly higher resistant subpopulation (on 1 mg/L CIP) at P1 (p=0.04), P2, P3

237 (p=0.001), P4 (p=0.003), P5 and P6 (p=0.002 and 0.003 respectively, t-test) (Figure1B). In $\Delta katA$
238 CIP-biofilm, there was a significant increase in the size of the resistant subpopulation developed
239 from P0 to P6 on 0.5 and 1 mg/L CIP (p=0.0001 and 0.001, t-test respectively).

240 Compared to the evolved CTRL populations (eight replicates), CIP-evolved biofilm $\Delta katA$
241 populations developed a significantly larger resistant subpopulation on 0.5, 1 (p<0.0001) and 2
242 mg/L CIP (p=0.01) (though for planktonic $\Delta katA$ only on 0.5 mg/L) (Figure 1A).

243 The ancestor $\Delta katA$ strain, which was used for initiating the evolution experiments, was tested for
244 the preexistence of resistant variants but no growth on 0.5, 1 and 2 mg/L CIP was observed;
245 indicating that the CIP resistant colonies were not present before the initial CIP treatment but
246 developed during the experimental evolution study.

247 Compared to WT PAO1(23), a higher CIP resistant subpopulation was observed in $\Delta katA$ at
248 passage 3 (p= 0.01), passage 4 (p=0.02), passage 5 (p=0.02) and passage 6 (p=0.03)(figure S1).

249 **Evolution of CIP resistance can occur in anaerobic evolved biofilms**

250 In order to investigate the role of oxygen for the CIP resistant development, we evolved PAO1 and
251 $\Delta katA$ colony biofilms in anaerobic chamber in the presence and absence of 0.1 mg/L CIP on LB
252 plates supplemented with 1 mM KNO₃, a concentration resembling the concentrations in CF
253 sputum(29). The size of the biofilm population was lower in anaerobic compared to aerobic
254 conditions, probably due to the consumption of KNO₃ during growth (table S1). We observed
255 occurrence of CIP resistant colonies (MIC = 1 mg/L) during anaerobic evolution with CIP in PAO1
256 (one of the two lineages) but not in $\Delta katA$ biofilm populations (not shown). The population
257 analysis of the anaerobically evolved biofilms showed that the percentage of CIP resistant
258 subpopulation on 1 mg/L CIP in one of the WT PAO1 lineages was 0, 0, 0.05, 0.26, 0.65, 0.33 from
259 passage 1 to passage 6, respectively.

260 This suggests that mutagenic mechanisms independent of ROS and RNS formation, such as SOS
261 response might play a role in mutagenesis towards ciprofloxacin in anaerobic conditions, as the
262 ones described in the CF mucus (30)(31).

263 **Hypermutators evolve in aerobic $\Delta katA$ biofilm populations and attain high MICs**

264 The mutation frequencies were measured in CIP biofilm and planktonic lineages throughout the
265 passages.

266 In one out of six independent replicate lineages of $\Delta katA$ biofilm, we observed increased mutation
267 frequencies corresponding to hypermutable phenotypes in the end of the experiment (P6) ($> 3 \times 10^{-7}$)
268 ⁷). Analysis of the mutation frequencies at the different passages in this lineage showed that already
269 after the first 48h exposure to ciprofloxacin (passage 0), the bacterial population had a
270 hypermutable phenotype and this was maintained during passages until the end of the evolution
271 experiment. This was not observed in the other biofilm or planktonic lineages of $\Delta katA$ or WT
272 PAO1.

273 The MIC for ciprofloxacin of the resistant isolates collected at the first and last passage of the
274 experimental evolution of $\Delta katA$ showed that the isolates with the highest MICs were selected from
275 the lineage with the hypermutable phenotype (Figure 2).

276 **Genetic evolution of biofilm and planktonic *P. aeruginosa* $\Delta katA$ under ciprofloxacin exposure 277 in aerobic conditions**

278 To get insight into the underlying genetic changes contributing to the accelerated development of
279 antibiotic resistance in biofilms in the absence of catalase, we sequenced the $\Delta katA$ populations at
280 the endpoint of the experimental evolution. A complete list of mutations in the different conditions

281 is presented in table S3. The identified genetic changes, defined as minimum variant frequency of
282 10%, were also compared to those observed in WT PAO1(23).

283 The highest number of mutations was observed in CIP-evolved biofilm populations of $\Delta katA$ (table
284 1).

285 According to gene functional categories, CIP treated $\Delta katA$ biofilm and planktonic populations have
286 a significantly higher number of mutations compared to CTRL populations in the category
287 “secreted factors (toxins, enzymes)” $p=0.044$ and 0.021 , respectively, t-test) (figure S2).

288 CIP-evolved $\Delta katA$ populations contain the largest number of mutations encountered with high
289 frequency compared to CTRL $\Delta katA$ populations but also compared to the WT PAO1 evolved in
290 the same conditions (Figure 3).

291 Large indels, inversions and duplications were present only in the CIP-evolved populations of
292 $\Delta katA$ and were not present in the populations of WT PAO1 evolved in the absence or presence of
293 CIP. The ratio between nonsynonymous and synonymous mutations $dN/dS > 1$ in $\Delta katA$ evolved
294 population suggest a positive selection for the described mutations which was not observed in the
295 evolved WT PAO1 populations ($dN/dS < 1$). Analysis of the mutational spectrum (table S2) revealed
296 that the most frequent mutation in $\Delta katA$ populations was transversion A:T-C:G. Mutations which
297 are repeatedly observed after independent exposures to a condition provide strong evidence of
298 adaptive evolution (Figure 3 and Table S3). This was the case for *nfxB*, a negative regulator of
299 MexCD-OprJ (32), (33) which was frequently and repeatedly mutated in $\Delta katA$ CIP biofilm evolved
300 populations as well as *pil* genes encoding for type IV pili, compared to CTRL biofilms. Mutations
301 in different other *mex* genes (*mexR*, *mexD*, *mexF*, *mexT*) or RND efflux pumps were also observed
302 in several lineages with lower frequencies. A large replacement of a 39 nucleotides with 31
303 nucleotides was observed in *mexT* in one of the CIP biofilm lineages (figureS3).

304 The genetic background of the observed hypermutable phenotype in one of the $\Delta katA$ CIP biofilm
305 lineages was shown to be an insertion of 27 nucleotides in *mutL* gene (codes for DNA mismatch
306 repair protein) (Figure S3) and as expected, the number of transitions in this lineage was higher
307 compared to the non-hypermutable lineages.

308 Mutation C1397T in *gyrB* coding for DNA gyrase subunit B, leading to an amino acid change
309 S466F was observed in the hypermutable lineages of the CIP-evolved $\Delta katA$ biofilms correlating to
310 the high CIP MIC of the resistant isolates from this lineage.

311 Mutations in either *mexR* or *nalD*, which are regulators of the MexAB-OprM efflux pump, were
312 frequent in CIP-exposed planktonic $\Delta katA$ lineages. Two different large indels were detected in
313 *mexR* in two lineages. (Figure S3)

314 In CIP-evolved biofilm $\Delta katA$ populations, genes related to iron acquisition and transport were
315 mutated in several lineages such as genes encoding for the siderophores pyoverdinin (*pvd*) and
316 pyochelin (*pch*); iron transporters (iron transport system permease HitB, as well as in
317 pyrroquinolone quinone biosynthesis genes (*pqq*) which are encoding a redox-sensing protein
318 (Table S2). In evolved biofilm and planktonic $\Delta katA$ populations, mutations in TonB-dependent
319 receptors were found. TonB proteins are essential components in iron-siderophore uptake in
320 bacteria (34) and mutations in these genes were not observed in the evolved populations of WT
321 PAO1.

322 In $\Delta katA$ CTRL biofilm compared to planktonic CTRL populations (evolved without CIP
323 exposure), *minC* which acts an inhibitor for cell division by inhibiting Z-ring assembly was
324 observed to be mutated in three different lineages.

325 **Genetic basis of resistance in CIP-resistant colonies isolated from anaerobically-evolved**
326 **biofilms**

327 The genetic basis of the six CIP resistant colonies (MIC= 1 mg/L) isolated from the anaerobically
328 evolved PAO1 biofilm was investigated by sequencing the *nfxB* gene and a CTTCT deletion at
329 position 162 leading to frameshift was found in all isolates.

330 Discussion

331 Evolution of *P. aeruginosa* biofilms under exposure to sub-inhibitory concentrations of CIP
332 resulted in a larger CIP-resistant subpopulation in $\Delta katA$ compared to WT PAO1 biofilm
333 populations indicating that the lack of KatA catalase accelerates the evolution of antibiotic
334 resistance in aerobic conditions. Given the role of KatA in the defense against oxidative and
335 nitrosative stress (20), we propose that these stresses play a role in the biofilm-related increased
336 mutagenesis in biofilms. Respiration by denitrification of biofilm-embedded *P. aeruginosa* exposed
337 to low-oxygen tension could be supported by the nitrate present in LB media (approx. 20 μ M NO³⁻
338)(29). In addition, it has been shown by transcriptomic (26) and proteomic studies (35) that under
339 CIP treatment *P. aeruginosa* switch to anaerobic respiration.

340 In support of the oxidative stress mechanism acting in $\Delta katA$ but not in WT PAO1 in aerobically-
341 evolved populations are the repeatedly observed mutations in iron assimilation genes, such as
342 mutations in genes encoding for TonB-dependent receptors which are essential for iron-siderophore
343 uptake in *P. aeruginosa*, mutations in genes encoding the siderophores pyoverdine and pyochelin
344 and in genes encoding various iron binding and redox-proteins (PQQ). Mutations in these genes
345 might represent a protective mechanism against iron uptake probably as a defense mechanism
346 against increased intracellular production of ROS by the Fenton reaction (36) as increased ROS
347 production was measured in $\Delta katA$ biofilms compared to WT PAO1 (8). Interestingly, it has been
348 reported that genes encoding TonB-dependent receptors were preferentially deleted in CF *P.*
349 *aeruginosa* isolates during adaptation in the CF lungs (34).

350 Although important for occurrence of mutagenic resistance in biofilms, oxidative stress is not the
351 only mechanism, as we have observed CIP resistant mutants also when PAO1 biofilms were
352 evolved in anaerobic conditions. It is unclear at the present time which mutagenesis mechanisms
353 occur in anaerobic conditions but one might consider the SOS stress response as a possible
354 mechanism.

355 However, this accelerated evolution of the antibiotic resistance in biofilms under exposure to sub-
356 inhibitory levels of ciprofloxacin in $\Delta katA$ compared to WT PAO1 aerobic biofilms was not
357 observed during the evolution in planktonic cultures (Figure S1). Although we do not have an
358 explanation for this, we can speculate that this might be due to accumulation of deleterious
359 mutations during evolution in the planktonic $\Delta katA$ population compared to WT PAO1.

360 Compared to planktonic populations, larger CIP resistant subpopulations were observed in biofilms
361 of both $\Delta katA$ and PAO1 (23) confirming that biofilm mode of growth promotes development of
362 mutational resistance in experimental evolution studies (Figure S1).

363 The genomic analysis of the aerobically evolved populations showed that the highest number of
364 mutations were observed in the CIP-evolved $\Delta katA$ biofilm populations and this is in agreement
365 with the hypothesis that ciprofloxacin exposure induces mutations either via SOS response or
366 through increased ROS levels in the catalase deficient mutants compared to WT PAO1 (37,3).

367 Analysis of the mutational spectra revealed that A:T-C:G transversion was the most frequent
368 mutation type in $\Delta katA$ populations and this has been previously shown to be related to unrepaired
369 oxidized guanine in the nucleotide pool (38). The genes belonging to the functional category of
370 secreted factors (toxins and enzymes) were also mutated in significantly higher number in CIP
371 evolved $\Delta katA$ biofilm and planktonic populations compared to CTRL biofilms and planktonic

372 populations and this is in accordance to our previous observations of loss of virulence factors during
373 evolution in the presence of CIP (26).

374 During the experimental evolution of $\Delta katA$ biofilms, *mutL* mutants with mutator phenotype and
375 high MICs of ciprofloxacin evolved corresponding with our previously study on the association
376 between bacterial hypermutability and chronic inflammation in chronically infected CF patients,
377 which is a source of chronic oxidative stress (25). The high MIC levels of ciprofloxacin in the
378 mutator lineage were found to be related to mutations in the CIP target gene, *gyrB*. Interestingly, a
379 mutation at the same site C1397T causing S466F has been previously found in planktonic
380 experimental evolution of a hypermutator strain due to impaired repair of oxidative lesions
381 (PAOMY-Mgm)(39) (40) and both amino acid changes have been described in levofloxacin non-
382 susceptible clinical *P. aeruginosa* isolates(41).

383 The genes found to be mutated in biofilms or planktonic evolution of both PAO1 and $\Delta katA$,
384 strongly suggest parallel and distinct evolutionary trajectories in the different mode of growth of *P.*
385 *aeruginosa*. Confirming previous results, the experimental evolution of biofilm and planktonic
386 $\Delta katA$ *P. aeruginosa* populations revealed that low-level CIP resistance evolves readily in biofilms
387 (23). For example, in CIP evolved $\Delta katA$ and WT PAO1 biofilms, mutations in the negative
388 regulator, *nfxB*, of the MexCD-OprJ efflux pump were frequently found. *nfxB* mutations have
389 previously been identified in *P. aeruginosa* isolates from CF patients (33). Mutations in *pil* genes
390 encoding for Type IV pili were mutated frequently in CIP evolved biofilm populations of both
391 $\Delta katA$ and WT PAO1. While in CIP evolved planktonic populations of both $\Delta katA$ and WT PAO1,
392 mutations in the negative regulator *mexR* and *nalD* of MexAB-OprM were found. These biofilm-
393 related low-level resistant subpopulations may accumulate further mutations which can further
394 increase the MIC of the population. This dynamic of resistance development under exposure to sub-
395 inhibitory levels of ciprofloxacin emphasizes the importance of treatment of the infections caused

396 by biofilm-growing *P. aeruginosa* with doses ensuring high antibiotic concentration at the site of
397 infection that can eliminate the first-step mutants or by combination therapy.

398 Mutations in the target genes of ciprofloxacin, *gyrA* and *B* were found only in the CIP-evolved
399 planktonic populations of WT PAO1(23)but not of non hypermutable $\Delta katA$ lineages, which
400 phenotypically correlated to high MIC levels in planktonic WT PAO1 but not $\Delta katA$ populations.

401 In conclusion, this study of the experimental evolution of $\Delta katA$ in biofilm and planktonic growth is
402 complementing earlier findings of the evolutionary study with PAO1, emphasizing the role of
403 environmental stresses such as oxidative, nitrosative stress and SOS responses for the mutational
404 landscape and the development of antibiotic resistance, which might play an important role in vivo
405 during chronic infections(42). A pitfall of all these correlative analysis between WGS and
406 phenotypic susceptibility is that it fails to capture the contribution of gene expression, an important
407 contributor to tolerance and resistance to antibiotics. Complementary analysis such as transcriptome
408 sequencing (RNA-seq) is the next step for correlating the susceptibility phenotype with genetic
409 content.

410 **Acknowledgements**

411 A.P. and M.O.A.S. acknowledge the Novo Nordisk Foundation under NFF grant number:
412 NNF10CC1016517, the European Union H2020 (ERC-2014-STG) under Grant Agreement 638902,
413 LimitMDR and the Danish Council for Independent Research, Sapere Aude Program DFF 4004-
414 00213.

415 The financial support of M.N.A. from the Egyptian Ministry of Higher Education is acknowledged.

416 The technical assistance of Tina Wassermann and Janna Baker are highly appreciated.

417 **Reference List**

418

- 419 1. **Stewart PS.** 2015. Antimicrobial Tolerance in Biofilms. *Microbiol.Spectr.***3**:
- 420 2. **Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, and Stewart PS.** 2004. Oxygen limitation
421 contributes to antibiotic tolerance of *Pseudomonas aeruginosa* in biofilms. *Antimicrob Agents*
422 *Chemother.***48**: 2659-2664.
- 423 3. **Boles BR and Singh PK.** 2008. Endogenous oxidative stress produces diversity and adaptability in
424 biofilm communities. *Proc Natl Acad Sci U S A.***105**: 12503-12508.
- 425 4. **Driffield K, Miller K, Bostock JM, O'Neill AJ, and Chopra I.** 2008. Increased mutability of
426 *Pseudomonas aeruginosa* in biofilms. *J Antimicrob Chemother.***61**: 1053-1056.
- 427 5. **Blazquez J, Couce A, Rodriguez-Beltran J, and Rodriguez-Rojas A.** 2012. Antimicrobials as promoters
428 of genetic variation. *Curr.Opin.Microbiol.***15**: 561-569.
- 429 6. **Dwyer DJ, Kohanski MA, and Collins JJ.** 2009. Role of reactive oxygen species in antibiotic action and
430 resistance. *Curr.Opin.Microbiol.***12**: 482-489.
- 431 7. **Gutierrez A, Stokes JM, and Matic I.** 2018. Our Evolving Understanding of the Mechanism of
432 Quinolones. *Antibiotics.(Basel).***7**:
- 433 8. **Jensen PO, Briaies A, Brochmann RP, Wang H, Kragh KN, Kolpen M, Hempel C, Bjarnsholt T, Hoiby**
434 **N, and Ciofu O.** 2014. Formation of hydroxyl radicals contributes to the bactericidal activity of
435 ciprofloxacin against *Pseudomonas aeruginosa* biofilms. *Pathog.Dis.***70**: 440-443.
- 436 9. **Aiassa V, Barnes AI, and Albesa I.** 2010. Resistance to ciprofloxacin by enhancement of antioxidant
437 defenses in biofilm and planktonic *Proteus mirabilis*. *Biochem.Biophys.Res.Commun.***393**: 84-
438 88.
- 439 10. **Van AH, Sass A, Bazzini S, De RK, Udine C, Messiaen T, Riccardi G, Boon N, Nelis HJ,**
440 **Mahenthalingam E, and Coenye T.** 2013. Biofilm-grown *Burkholderia cepacia* complex cells
441 survive antibiotic treatment by avoiding production of reactive oxygen species. *PLoS.One.***8**:
442 e58943
- 443 11. **Jensen PO, Lykkesfeldt J, Bjarnsholt T, Hougen HP, Hoiby N, and Ciofu O.** 2012. Poor antioxidant
444 status exacerbates oxidative stress and inflammatory response to *Pseudomonas aeruginosa*
445 lung infection in guinea pigs. *Basic Clin.Pharmacol.Toxicol.***110**: 353-358.
- 446 12. **Elkins JG, Hassett DJ, Stewart PS, Schweizer HP, and McDermott TR.** 1999. Protective role of
447 catalase in *Pseudomonas aeruginosa* biofilm resistance to hydrogen peroxide.
448 *Appl.Environ.Microbiol.***65**: 4594-4600.
- 449 13. **Stewart PS, Roe F, Rayner J, Elkins JG, Lewandowski Z, Ochsner UA, and Hassett DJ.** 2000. Effect of
450 catalase on hydrogen peroxide penetration into *Pseudomonas aeruginosa* biofilms. *Appl*
451 *Environ Microbiol.***66**: 836-838.
- 452 14. **Kohanski MA, Dwyer DJ, and Collins JJ.** 2010. How antibiotics kill bacteria: from targets to networks.
453 *Nat.Rev.Microbiol.***8**: 423-435.

- 454 15. **Liu Y and Imlay JA.** 2013. Cell death from antibiotics without the involvement of reactive oxygen
455 species. *Science*.**339**: 1210-1213.
- 456 16. **Hasset DJ and Imlay JA.** 2007. Bactericidal antibiotics and oxidative stress: a radical proposal. *ACS*
457 *Chem.Biol.***2**: 708-710.
- 458 17. **Keren I, Wu Y, Inocencio J, Mulcahy LR, and Lewis K.** 2013. Killing by bactericidal antibiotics does not
459 depend on reactive oxygen species. *Science*.**339**: 1213-1216.
- 460 18. **Khakimova M, Ahlgren HG, Harrison JJ, English AM, and Nguyen D.** 2013. The stringent response
461 controls catalases in *Pseudomonas aeruginosa* and is required for hydrogen peroxide and
462 antibiotic tolerance. *J.Bacteriol.***195**: 2011-2020.
- 463 19. **Martins D, McKay G, Sampathkumar G, Khakimova M, English AM, and Nguyen D.** 2018. Superoxide
464 dismutase activity confers (p)ppGpp-mediated antibiotic tolerance to stationary-phase
465 *Pseudomonas aeruginosa*. *Proc.Natl.Acad.Sci.U.S.A.***115**: 9797-9802.
- 466 20. **Su S, Panmanee W, Wilson JJ, Mahtani HK, Li Q, Vanderwielen BD, Makris TM, Rogers M, McDaniel**
467 **C, Lipscomb JD, Irvin RT, Schurr MJ, Lancaster JR, Jr., Kovall RA, and Hasset DJ.** 2014.
468 Catalase (KatA) plays a role in protection against anaerobic nitric oxide in *Pseudomonas*
469 *aeruginosa*. *PLoS.One.***9**: e91813
- 470 21. **Chung IY, Kim BO, Jang HJ, and Cho YH.** 2016. Dual promoters of the major catalase (KatA) govern
471 distinct survival strategies of *Pseudomonas aeruginosa*. *Sci.Rep.***6**: 31185
- 472 22. **Hasset DJ, Ma JF, Elkins JG, McDermott TR, Ochsner UA, West SE, Huang CT, Fredericks J, Burnett**
473 **S, Stewart PS, McFeters G, Passador L, and Iglewski BH.** 1999. Quorum sensing in
474 *Pseudomonas aeruginosa* controls expression of catalase and superoxide dismutase genes
475 and mediates biofilm susceptibility to hydrogen peroxide. *Mol Microbiol.***34**: 1082-1093.
- 476 23. **Ahmed MN, Porse A, Sommer MOA, Hoiby N, and Ciofu O.** 2018. Evolution of Antibiotic Resistance
477 in Biofilm and Planktonic *Pseudomonas aeruginosa* Populations Exposed to Subinhibitory
478 Levels of Ciprofloxacin. *Antimicrob.Agents Chemother.***62**:
- 479 24. **Walters MC, III, Roe F, Bugnicourt A, Franklin MJ, and Stewart PS.** 2003. Contributions of antibiotic
480 penetration, oxygen limitation, and low metabolic activity to tolerance of *Pseudomonas*
481 *aeruginosa* biofilms to ciprofloxacin and tobramycin. *Antimicrob Agents Chemother.***47**: 317-
482 323.
- 483 25. **Ciofu O, Riis B, Pressler T, Poulsen HE, and Hoiby N.** 2005. Occurrence of hypermutable
484 *Pseudomonas aeruginosa* in cystic fibrosis patients is associated with the oxidative stress
485 caused by chronic lung inflammation. *Antimicrob Agents Chemother.***49**: 2276-2282.
- 486 26. **Wassermann T, Meinike JK, Ivanyshyn K, Bjarnsholt T, Khademi SM, Jelsbak L, Hoiby N, and Ciofu O.**
487 2016. The phenotypic evolution of *Pseudomonas aeruginosa* populations changes in the
488 presence of subinhibitory concentrations of ciprofloxacin. *Microbiology.***162**: 865-875.
- 489 27. **Yang L, Jelsbak L, Marvig RL, Damkiaer S, Workman CT, Rau MH, Hansen SK, Folkesson A, Johansen**
490 **HK, Ciofu O, Hoiby N, Sommer MO, and Molin S.** 2011. Evolutionary dynamics of bacteria in
491 a human host environment. *Proc.Natl.Acad.Sci.U.S.A.***108**: 7481-7486.

- 492 28. **Zaborskyte G, Andersen JB, Kragh KN, and Ciofu O.** 2016. Real-time monitoring of nfxB mutant
493 occurrence and dynamics in *P. aeruginosa* biofilm exposed to sub-inhibitory concentrations
494 of ciprofloxacin. *Antimicrob.Agents Chemother.*
- 495 29. **Line L, Alhede M, Kolpen M, Kuhl M, Ciofu O, Bjarnsholt T, Moser C, Toyofuku M, Nomura N, Hoiby**
496 **N, and Jensen PO.** 2014. Physiological levels of nitrate support anoxic growth by
497 denitrification of *Pseudomonas aeruginosa* at growth rates reported in cystic fibrosis lungs
498 and sputum. *Front Microbiol.*5: 554
- 499 30. **Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss**
500 **T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, and Doring G.** 2002. Effects of
501 reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis
502 patients. *J Clin Invest.*109: 317-325.
- 503 31. **Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van GM, Ciofu O, Mandsberg L,**
504 **Kharazmi A, Doring G, Givskov M, Hoiby N, and Jensen PO.** 2010. Polymorphonuclear
505 leucocytes consume oxygen in sputum from chronic *Pseudomonas aeruginosa* pneumonia in
506 cystic fibrosis. *Thorax.*65: 57-62.
- 507 32. **Poole K.** 2007. Efflux pumps as antimicrobial resistance mechanisms. *Ann.Med.*39: 162-176.
- 508 33. **Imamovic L, Ellabaan MMH, Dantas Machado AM, Citterio L, Wulff T, Molin S, Krogh JH, and**
509 **Sommer MOA.** 2018. Drug-Driven Phenotypic Convergence Supports Rational Treatment
510 Strategies of Chronic Infections. *Cell.*172: 121-134.
- 511 34. **Dingemans J, Ye L, Hildebrand F, Tontodonati F, Craggs M, Bilocq F, De VD, Crabbe A, Van HR,**
512 **Malfroot A, and Cornelis P.** 2014. The deletion of TonB-dependent receptor genes is part of
513 the genome reduction process that occurs during adaptation of *Pseudomonas aeruginosa* to
514 the cystic fibrosis lung. *Pathog.Dis.*71: 26-38.
- 515 35. **Peng J, Cao J, Ng FM, and Hill J.** 2017. *Pseudomonas aeruginosa* develops Ciprofloxacin resistance
516 from low to high level with distinctive proteome changes. *J.Proteomics.*152: 75-87.
- 517 36. **Touati D.** 2000. Iron and oxidative stress in bacteria. *Arch.Biochem.Biophys.*373: 1-6.
- 518 37. **Blazquez J, Rodriguez-Beltran J, and Matic I.** 2018. Antibiotic-Induced Genetic Variation: How It
519 Arises and How It Can Be Prevented. *Annu.Rev.Microbiol.*72: 209-230.
- 520 38. **Sanders LH, Sudhakaran J, and Sutton MD.** 2009. The GO system prevents ROS-induced mutagenesis
521 and killing in *Pseudomonas aeruginosa*. *FEMS Microbiol.Lett.*294: 89-96.
- 522 39. **Mandsberg LF, Macia MD, Bergmann KR, Christiansen LE, Alhede M, Kirkby N, Hoiby N, Oliver A,**
523 **and Ciofu O.** 2011. Development of antibiotic resistance and up-regulation of the
524 antimutator gene *pfpl* in mutator *Pseudomonas aeruginosa* due to inactivation of two DNA
525 oxidative repair genes (*mutY, mutM*). *FEMS Microbiol Lett.*324: 28-37.
- 526 40. **Jørgensen KM, Wassermann T, Jensen PO, Hengzuang W, Molin S, Hoiby N, and Ciofu O.** 2013.
527 Sublethal Ciprofloxacin Treatment Leads to Rapid Development of High-Level Ciprofloxacin
528 Resistance during Long-Term Experimental Evolution of *Pseudomonas aeruginosa*.
529 *Antimicrob.Agents Chemother.*57: 4215-4221.

Evolution of resistance in *P. aeruginosa* $\Delta katA$ biofilms

Ahmed, M. et al.

- 530 41. **Kos VN, Deraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, and Gardner H.** 2015.
531 The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility.
532 *Antimicrob. Agents Chemother.* **59**: 427-436.
- 533 42. **Crabbe A, Jensen PO, Bjarnsholt T, and Coenye T.** 2019. Antimicrobial Tolerance and Metabolic
534 Adaptations in Microbial Biofilms. *Trends Microbiol.*
535
536
- 537

	Insertions /deletions	Transitions	Transversions	Large indels	Inversions Duplications	Total number of mutations	dN/dS
PAO1 *							
CTRL biofilm	24 (28%)	13 (15%)	48 (56%)			85	0.35
CTRL planktonic	24 (26%)	22 (23%)	48 (51%)			94	0.25
CIP biofilm	60 (37%)	27 (16%)	77 (47%)			164	0.44
CIP planktonic	29 (22%)	44 (34%)	57 (44%)			130	0.45
$\Delta katA$							
CTRL biofilm	147 (22%)	58 (9%)	452 (69%)		1	658	1.36
CTRL planktonic	141 (24%)	70 (12%)	362 (63%)		5	578	1.24
CIP biofilm	301 (28%)	206 (19%)	557 (52%)	2	9	1075	0.90
CIP planktonic	150 (22%)	65 (10%)	469 (69%)	6	7	697	2.59

538 Table 1.


539

540 Table 1. The types of mutations (number and % of total number of mutations in the populations) in
541 WT PAO1 and $\Delta katA$ *P. aeruginosa* evolved populations. The ratio between the
542 nonsynonymous/synonymous mutations (dN/dS) is presented. * the number and types of mutations
543 in PAO1 evolved populations has been re-analyzed including non-synonymous mutations in
544 hypothetical proteins (not included in (23)).

545

546

547 Figure 1A.




548

549 Figure 1A. The size of *P. aeruginosa* $\Delta katA$ (KatA) biofilm(biofilm)and planktonic (PLA)
550 populations recovered from 0.5, 1 and 2 mg/L CIP after evolution in the presence of CIP (0.1 mg/l)
551 or in the absence of antibiotic (CTRL). The values represent the mean (SEM) of the replicates for
552 each growth condition. * significantly larger population compared to control populations, **
553 significantly larger population in biofilm compared to planktonic population.

554

555 Figure 1B.




556

557 Figure 1B. The development of CIP resistance in $\Delta katA$ biofilm (biofilm) and planktonic (PLA)
558 populations recovered from 1 mg/L CIP during passages (P0 to P6). Under exposure to
559 ciprofloxacin, $\Delta katA$ CIP-biofilm populations developed a significantly higher resistant
560 subpopulation compared to planktonic populations at P1, P2, P3, P4, P5 and P6 ($p=0.04, 0.001,$
561 $0.001, 0.003, 0.002$ and 0.003 respectively). The values represent the mean (SEM) for replicates for
562 each growth condition.

563

564 Figure 2.



565

566 Figure 2. The MIC of ciprofloxacin (mg/L) of resistant colonies isolated from CIP plates of the
 567 $\Delta katA$ *P. aeruginosa* population analysis from the hypermutable lineage (HP) and the
 568 nonhypermutable (NHp) lineages.

569

570

571

572

573

574

575

576

579 Figure 3. The frequency (%) of each mutation (y axis) and their genomic location (x axis) in the
580 WT PAO1 (A) and $\Delta katA$ (B) biofilm and planktonic populations in the different conditions. Red
581 bars represent mutations with frequencies > 50% and green bars represent mutations with
582 frequencies < 50%. The blue circles are marking genes with mutations at the same position
583 occurring in several lineages with similar frequencies.

584

585

586

587

588

589

590

591

592

593

594

595

Evolution of resistance in *P. aeruginosa* $\Delta katA$ biofilms

Ahmed, M. et al.

596